natgillin/translations-raw huggingface dataset:
The company informed the CHMP that there are no consequences for patients included in ongoing clinical trials.
Družba je CHMP obvestila, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih.
Withdrawal of the marketing authorisation application for Luveniq (voclosporin) EMA/CHMP/835463/2011
Umik vloge za pridobitev dovoljenja za promet z zdravilom Luveniq (voklosporin) EMA/CHMP/835463/2011
It belongs to the class of calcineurin inhibitors.
Spada v skupino zaviralcev kalcinevrina.
The main measure of effectiveness was how the inflammation of the eye improved after 16 weeks and 24 weeks of treatment, measured by looking at the change in the amount of vitreous haze (clouding of the vitreous humour, the clear gel between the lens and the retina of the eyeball).
Glavno merilo učinkovitosti je bilo izboljšanje vnetja očesa po 16 in 24 tednih zdravljenja, izmerjeno na osnovi spremembe motnosti (motnosti steklovine, bistrega gela med lečo in mrežnico v očesnem zrklu).
Luveniq also caused side effects which are known to occur with this type of immunosuppressive medicine, including hypertension (high blood pressure).
Zdravilo Luveniq je povzročilo neželene učinke, ki so znani za tovrstna imunosupresivna zdravila, vključno s hipertenzijo (zvišan krvni tlak).
The application was supported by one main study involving 218 patients with non-infectious uveitis which compared Luveniq with placebo.
Družba je vlogo podprla z eno glavno študijo z 218 bolniki z neinfektivnim uveitisom, v kateri so zdravilo Luveniq primerjali s placebom.
Withdrawal of the marketing authorisation application for Luveniq (voclosporin)
Umik vloge za pridobitev dovoljenja za promet z zdravilom Luveniq (voklosporin)
It targets T-cells, a type of white blood cell in the immune system that is particularly active in inflammation.
Učinkuje na celice T, vrsto levkocitov imunskega sistema, ki so še posebej aktivni pri vnetju.
Luveniq is an immunosuppressive agent, which means that it reduces the activity of the immune system.
Zdravilo Luveniq je imunosupresivno sredstvo, kar pomeni, da zmanjša aktivnost imunskega sistema.
What is Luveniq?
Kaj je zdravilo Luveniq?
Luveniq was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 14 September 2007 for the treatment of chronic non-infectious uveitis.
Zdravilo Luveniq je bilo dne 14. septembra 2007 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni) za zdravljenje kroničnega neinfektivnega uveitisa.
Luveniq is a medicine that contains the active substance voclosporin.
Luveniq je zdravilo, ki vsebuje zdravilno učinkovino voklosporin.
Therefore, the CHMP was of the opinion that the benefits of Luveniq had not been shown to outweigh its risks and recommended that it be refused marketing authorisation.
CHMP je menil, da ni bilo dokazano, da koristi zdravila Luveniq odtehtajo z njim povezana tveganja, zato je priporočil zavrnitev vloge za pridobitev dovoljenja za promet.
What was Luveniq expected to be used for?
Za kaj naj bi se zdravilo Luveniq uporabljalo?
It was expected to decrease the inflammation seen in uveitis by blocking an enzyme called calcineurin which is involved in activating Tcells.
Zdravilo naj bi zmanjšalo vnetje pri uveitisu z blokiranjem encima, imenovanega kalcinevrin, ki sodeluje pri aktivaciji celic T.
On 13 October 2011, Lux Biosciences GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Luveniq, for the treatment of chronic active non-infectious uveitis involving the intermediate or posterior segments of the eye.
Družba Lux Biosciences GmbH je dne 13. oktobra 2011 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Luveniq, namenjenim zdravljenju kroničnega aktivnega neinfektivnega uveitisa, ki je zajel vmesni in zadajšnji očesni prekat.
What did the company present to support its application?
Katero dokumentacijo je družba predložila CHMP v podporo svoji vlogi?
Based on the review of the data, at the time of the withdrawal, the CHMP had previously given a negative opinion in June 2011 recommending that the marketing authorisation be refused for Luveniq for the treatment of chronic active non-infectious uveitis involving the intermediate or posterior segments of the eye.
Na podlagi pregleda podatkov je Odbor v času umika vloge junija 2011 izrazil negativno mnenje in priporočil zavrnitev vloge za pridobitev dovoljenja za promet z zdravilom Luveniq za zdravljenje kroničnega aktivnega neinfektivnega uveitisa, ki je zajel vmesni in zadajšnji očesni prekat.
How is Luveniq expected to work?
Kako naj bi zdravilo Luveniq delovalo?
Only one main study supported the application and the results did not show in a robust way that Luveniq was more effective than placebo at reducing eye inflammation, while no difference was seen in the patients' eyesight compared with placebo.
Njeni rezultati niso pokazali na robusten način, da je zdravilo Luveniq učinkovitejše od placeba pri zmanjšanju vnetja očesa.
Luveniq was expected to be used to treat chronic active non-infectious uveitis involving the intermediate or posterior segments of the eye. Uveitis is inflammation of the uvea (the middle layer of the eye) which can lead to loss of vision.
Zdravilo Luveniq naj bi se uporabljalo za zdravljenje kroničnega aktivnega neinfektivnega uveitisa, ki je zajel vmesni in zadajšnji očesni prekat.
At the time of the negative opinion, the CHMP was not convinced that the benefits of Luveniq had been shown to outweigh the risks as a treatment for chronic non-infectious uveitis.
Zato je CHMP v času umika menil, da koristi zdravila Luveniq za zdravljenje kroničnega neinfektivnega uveitisa ne odtehtajo z njim povezanih tveganj.
Pharmaceutical Form
Jakost Farmacevtska oblika Pot uporabe
EU/1/11/742/001
90 (3 x 30 x 1) tablet (enoodmerni pretisni omot) (zloženka: škatla)
The patient should take one tablet once a day with a light meal, preferably at the same time each day.
Bolnik mora vzeti eno tableto sočasno z lahkim obrokom enkrat na dan, najbolje vsak dan ob istem času.
The European Commission granted a marketing authorisation valid throughout the European Union for Rasilamlo on 14 April 2011.
Evropska komisija je dovoljenje za promet z zdravilom Rasilamlo, veljavno po vsej Evropski uniji, izdala 14. aprila 2011.
The full EPAR for Rasilamlo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rasilamlo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Rasilamlo?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rasilamlo?
This is a summary of the European public assessment report (EPAR) for Rasilamlo.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rasilamlo.
Rasilamlo aliskiren / amlodipine
Rasilamlo aliskiren/amlodipin
It should not be taken together with fruit juice or drinks containing plant extracts such as herbal teas.
Zdravila se ne sme jemati skupaj s sadnim sokom ali pijačami, ki vsebujejo rastlinske izvlečke, kot so na primer zeliščni čaji.
The main measure of effectiveness was the change in the average diastolic blood pressure (blood pressure measured between two heartbeats) measured when the patients were seated.
Glavno merilo učinkovitosti je bila sprememba povprečnega diastoličnega krvnega tlaka (krvnega tlaka, merjenega med dvema utripoma srca), izmerjenega pri bolniku v sedečem položaju.
Other information about Rasilamlo
Druge informacije o zdravilu Rasilamlo
A risk management plan has been developed to ensure that Rasilamlo is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Rasilamlo je bil pripravljen načrt obvladovanja tveganj.
What benefit has Rasilamlo shown during the studies?
Kakšne koristi je zdravilo Rasilamlo izkazalo med študijami?
The CHMP decided that Rasilamlo's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rasilamlo večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rasilamlo.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
For more information about treatment with Rasilamlo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Rasilamlo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In three main studies involving 2,212 patients Rasilamlo was compared with aliskiren or amlodipine taken alone for eight or six weeks.
V treh glavnih študijah, v katere je bilo vključenih 2 212 bolnikov, so zdravilo Rasilamlo osem ali šest tednov primerjali z aliskirenom ali amlodipinom kot samostojnima zdraviloma.
What is the risk associated with Rasilamlo?
Kakšna tveganja so povezana z zdravilom Rasilamlo?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rasilamlo, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Rasilamlo is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.
Ne sme se uporabljati pri otrocih, mlajših od dveh let, medtem ko njegova uporaba pri starejših otrocih ni priporočljiva.
It must also not be used in women who are more than three months pregnant or in patients taking medicines containing ciclosporin, itraconazole or other medicines known as ‘potent Pglycoprotein inhibitors' (such as quinidine).
Prav tako ga ne smejo uporabljati ženske, ki so noseče več kot tri mesece, ali bolniki, ki jemljejo zdravila, ki vsebujejo ciklosporin in itrakonazol, ali druga zdravila, znana kot močni zaviralci P-glikoproteina (kot je kinidin).
It is available as tablets (150 mg aliskiren and 5 mg amlodipine; 150 mg aliskiren and 10 mg amlodipine; 300 mg aliskiren and 5 mg amlodipine; 300 mg aliskiren and 10 mg amlodipine).
Na voljo je v obliki tablet (150 mg aliskirena in 5 mg amlodipina; 150 mg aliskirena in 10 mg amlodipina; 300 mg aliskirena in 5 mg amlodipina; 300 mg aliskirena in 10 mg amlodipina).
Rasilamlo is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.
Zdravilo Rasilamlo se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih, pri katerih krvni tlak ni ustrezno uravnan z jemanjem samo aliskirena ali amlodipina.
Rasilamlo must not be used in people who are hypersensitive (allergic) to aliskiren, amlodipine, to any of the other ingredients of the medicine or other substances derived from dihydropyridine (a group that includes amlodipine).
Zdravila Rasilamlo ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aliskiren, amlodipin ali katero koli drugo sestavino zdravila ali druge snovi, pridobljene iz dihidropiridina (skupine zdravil, v katero spada tudi amlodipin).
The most common side effects with Rasilamlo are hypotension (low blood pressure) and peripheral oedema (swelling, especially of the ankles and feet).
Najpogostejša neželena učinka zdravila Rasilamlo sta hipotenzija (nizek krvni tlak) in periferni edemi (otekanje, zlasti gležnjev in stopal).
The dose may be adjusted based on the side effects the patient experienced with their previous treatment with aliskiren or amlodipine and also on how the patient responds to treatment with Rasilamlo.
Odmerek se lahko prilagodi glede na neželene učinke, ki so se pri bolniku pojavljali med predhodnim zdravljenjem z aliskirenom ali amlodipinom, ter glede na njegov odziv na zdravljenje z zdravilom Rasilamlo.
The strength of the tablet the patient takes depends on the doses of aliskiren or amlodipine that they received previously.
Jakost tablete, ki jo bolnik jemlje, je odvisna od odmerkov aliskirena ali amlodipina, ki ju je bolnik jemal pred tem.
It must not be used in patients with a history of angioedema (swelling beneath the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, severe hypotension, shock, narrowing of the aortic heart valve or in patients with heart failure after a heart attack.
Ne smejo ga uporabljati bolniki, pri katerih se je zaradi jemanja aliskirena pojavil angioedem (podkožno otekanje), bolniki z dednim angioedemom ali angioedemom brez očitnega vzroka, osebe s hudo hipotenzijo, osebe v šoku, osebe z zoženjem aortne srčne zaklopke in bolniki s srčnim popuščanjem po srčni kapi.
For the full list of all side effects reported with Rasilamlo, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rasilamlo, glejte navodilo za uporabo.
How has Rasilamlo been studied?
Kako je bilo zdravilo Rasilamlo raziskano?
Why has Rasilamlo been approved?
Zakaj je bilo zdravilo Rasilamlo odobreno?
Rasilamlo can be used with other antihypertensive medicines, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Rasilamlo se lahko uporablja sočasno z drugimi zdravili za zdravljenje hipertenzije z izjemo zaviralcev angiotenzinske konvertaze (ACE) ali zaviralcev angiotenzinskih receptorjev (ARB) pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
In the first study, patients taking Rasilamlo 300/10 mg and 300/5 mg had a fall in their sitting diastolic blood pressure of 13.1 mmHg and 10.5 mmHg, respectively, compared with a fall of 5.8 mmHg in patients taking aliskiren 300 mg.
V prvi študiji se je pri bolnikih, ki so jemali zdravilo Rasilamlo v odmerku 300/10 mg oz. 300/5 mg, diastolični krvni tlak v sedečem položaju znižal za 13,1 mmHg oz. 10,5 mmHg v primerjavi z znižanjem za 5,8 mmHg pri bolnikih, ki so jemali 300 mg aliskirena.
Rasilamlo was more effective at controlling essential hypertension than placebo, aliskiren or amlodipine used alone.
Zdravilo Rasilamlo je bilo pri uravnavanju esencialne hipertenzije učinkovitejše od placeba, aliskirena ali amlodipina kot samostojnih zdravil.
Rasilamlo is a medicine that contains the active substances aliskiren and amlodipine.
Rasilamlo je zdravilo, ki vsebuje zdravilni učinkovini aliskiren in amlodipin.
It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Zavira dejavnost človeškega encima, imenovanega renin, ki v telesu sodeluje pri tvorjenju angiotenzina I. Angiotenzin I se pretvori v hormon angiotenzin II, ki deluje kot močan vazokonstriktor (učinkovina, ki oži žile).
The third study showed a fall in blood pressure of 8.5 mmHg with Rasilamlo 150/5 mg compared with 8.0 mmHg and 4.8 mmHg with amlodipine 10 mg and 5 mg, respectively.
V tretji študiji se je pri jemanju zdravila Rasilamlo v odmerku 150/5 mg krvni tlak znižal za 8,5 mmHg v primerjavi z 8,0 mmHg oz. 4,8 mmHg pri jemanju amlodipina v odmerku 10 mg oz. 5 mg.
Rasilamlo contains two active substances, aliskiren and amlodipine.
Zdravilo Rasilamlo vsebuje dve zdravilni učinkovini, aliskiren in amlodipin.
What is Rasilamlo used for?
Za kaj se zdravilo Rasilamlo uporablja?
In the second study the falls in blood pressure were 11.0 mmHg and 9.0 mmHg with Rasilamlo 300/10 mg and 150/10mg, respectively, compared with 7.2mmHg with amlodipine 10 mg.
V drugi študiji se je pri jemanju zdravila Rasilamlo v odmerku 300/10 mg oz. 150/10 mg krvni tlak znižal za 11,0 mmHg oz. 9,0 mmHg v primerjavi z znižanjem za 7,2 mmHg pri jemanju 10 mg amlodipina.
Rasilamlo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Rasilamlo se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
How is Rasilamlo used?
Kako se zdravilo Rasilamlo uporablja?
How does Rasilamlo work?
Kako zdravilo Rasilamlo deluje?
Not known (frequency cannot be estimated from the available data)
Pogostnost neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
If renal dysfunction is observed, appropriate management and treatment should be prescribed in accordance with standard treatment guidelines.
Če se ugotovi ledvična disfunkcija, je treba predpisati ustrezno obvladovanje in zdravljenje skladno s standardnimi smernicami.
OTHER SPECIAL WARNING(S), IF NECESSARY Use only as directed by a doctor.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Uporabljajte samo po zdravnikovih navodilih.
For CML, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment.
Pri zdravljenju KML vam lahko zdravnik predpiše večji ali manjši odmerek, odvisno od tega, kako se odzivate na zdravljenje.
If you have any questions about how Imatinib Accord works or why this medicine has been prescribed for you, ask your doctor.
Če imate kakšna vprašanja glede tega, kako zdravilo Imatinib Accord deluje ali zakaj vam je bilo predpisano to zdravilo, vprašajte svojega zdravnika.
235 adult patients with accelerated phase disease were enrolled.
Vključili so 235 odraslih bolnikov s pospešeno fazo bolezni.
Some children and adolescents taking Imatinib Accord may have slower than normal growth.
Pri nekaterih otrocih in mladostnikih, ki jemljejo zdravilo Imatinib Accord, je lahko rast počasnejša od normalne.
Other adverse reactions were reported with lower or equal frequency.
Pri drugih neželenih reakcijah so poročali o manjši ali enaki pogostosti.
Frequency categories are defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The amount of Imatinib Accord given will depend on your child's condition, body weight and height.
Potrebna količina zdravila Imatinib Accord bo odvisna od otrokovega stanja, telesne mase in višine.
Study ADE04 Prephase
Študija ADE04 predhodna faza
• Do not use any pack that is damaged or shows signs of tampering.
• Ne uporabite škatle, če je poškodovana ali kaže znake, da je bila že odprta.
In all clinical studies 38-40% of patients were > 60 years of age and 10-12% of patients were > 70 years of age.
V vseh kliničnih študijah je bilo 38-40 % bolnikov starih  60 let, 10-12 % bolnikov pa je bilo starih  70 let.
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice:
Če tablet ne morete pogoltniti, jih lahko raztopite v kozarcu navadne vode ali jabolčnega soka:
Median age was 51 years (range 18-70 years), with 21.9% of patients ≥ 60 years of age.
Povprečna starost je bila 51 let (razpon 18-70 let), 21,9 % bolnikov je bilo starih ≥ 60 let.
Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF).
Bolnikom je treba naročiti, naj se poslužujejo ukrepov, kot so zaščita z oblačili in uporaba zaščitne kreme z visokim zaščitnim faktorjem (SPF - sun protection factor).
Date of first authorization: 01 July 2013 Date of latest renewal: 19th April 2018
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve pridobitve dovoljenja za promet: 1. julij 2013 Datum podaljšanja dovoljenja za promet: 19. april 2018
Ki values in human liver microsomes were 27, 7.5 and 7.9 mol/l, respectively.
Vrednosti Ki v mikrosomih človeških jeter so bile 27, 7,5 oziroma 7,9 μmol/l.
Other side effects may include
Drugi neželeni učinki lahko vključujejo
The decreases in white blood cell (WBC) and neutrophil counts occurred mainly during the first six weeks of therapy, with values remaining relatively stable thereafter.
Do zmanjšanja koncentracij belih krvničk (WBC) in nevtrofilcev je prišlo predvsem v prvih šestih tednih zdravljenja, zatem pa so vrednosti ostale relativno stabilne.
Healthcare professionals are asked to report any suspected adverse reactionsvia the national reporting system listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
Dermatofibrosarcoma protuberans (DFSP).
- s protuberantnim dermatofibrosarkomom (DFSP).
Imatinib pharmacokinetics have not been specifically studied in elderly.
Farmakokinetike imatiniba pri starejših niso posebej proučili.
No specific dose recommendation is necessary in elderly.
Pri starejših niso potrebna posebna priporočila glede odmerjanja.
The safety database for children and adolescents with Ph+ALL is very limited though no new safety concerns have been identified.
Čeprav je baza podatkov za otroke in mladostnike s Ph+ ALL zelo majhna, zaenkrat niso odkrili nobenih novih pomislekov glede varnosti.
For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of mineral water or apple juice.
Bolnikom, ki ne morejo pogoltniti filmsko obloženih tablet, lahko tablete raztopimo v kozarcu mineralne vode ali jabolčnega soka.
Chronic phase, newly diagnosed
Kronična faza, na novo diagnosticirana
- Imatinib Accord is not recommended during pregnancy unless clearly necessary as it may harm your baby.
- Uporabe zdravila Imatinib Accord v nosečnosti ne priporočamo, če to ni nujno potrebno, saj lahko škoduje vašemu otroku.
Your doctor has prescribed Imatinib Accord because you suffer from a serious condition.
Zdravnik vam je predpisal zdravilo Imatinib Accord, ker imate resno bolezen.
Your doctor will discuss with you the possible risks of taking Imatinib Accord during pregnancy.
Zdravnik se bo pogovoril z vami o možnih nevarnostih jemanja zdravila Imatinib Accord v nosečnosti.
Since increased vascularity and propensity for bleeding is a part of the nature and clinical course of GIST, standard practices and procedures for the monitoring and management of haemorrhage in all patients should be applied.
Ker sta povečana vaskularnost in nagnjenje h krvavitvam del narave in kliničnega poteka GIST, je treba pri vseh bolnikih uporabiti standardne prakse in postopke za spremljanje in zdravljenje krvavitev.
Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients.
Pri tem je pomembno, da je 27,7 % bolnikov doseglo tudi pomemben citogenetični odziv, ki je bil pri 20,4 % bolnikov popoln (potrjen pri 16 %).
Major cytogenetic response Complete (Confirmed
Pomemben citogenetični odziv popoln (potrjen
What Imatinib Accord is and what it is used for What you need to know before you take Imatinib Accord How to take Imatinib Accord Possible side effects
Kaj je zdravilo Imatinib Accord in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Imatinib Accord Kako jemati zdravilo Imatinib Accord Možni neželeni učinki
5 patients responded, 3 completely and 2 partially.
Do odziva je prišlo pri 5 bolnikih, pri 3 do popolnega in pri 2 do delnega.